Low Serum IGF1 Predicts CV Events in RA Women
By LabMedica International staff writers Posted on 06 Aug 2019 |
Image: The cobas e 801 module is a high throughput immunochemistry module that performs a broad range of heterogeneous immunoassay tests (Photo courtesy of Roche Diagnostics).
Hypertension is a significant health threat and an independent predictor of cardiovascular (CV) events including coronary heart disease, stroke, heart failure, and dementia in the general population and in rheumatoid arthritis (RA).
Solid biological evidence connects insulin-like growth factor 1 (IGF1) with the regulation of endothelial cell function. Circulating IGF1 is known to induce vasodilation, which contributes to the regulation of arterial blood pressure (BP) and vascular tone. Disturbances in IGF1/ IGF1 receptor (IGF1R) signaling are notable for RA pathology.
Scientists at Sahlgrenska University Hospital (Gothenburg, Sweden) and their colleagues consecutively enrolled 184 female RA patients. All the patients fulfilled the classification criteria for RA and had median disease duration of seven years. The dominating majority (89%) were Rheumatoid factor (RF) and/or Anti–citrullinated protein antibody (ACPA) positive. For serum preparation, the blood was obtained from the cubital vein into vacuum containers and for RNA preparation into PAXgene protection tubes. Serum samples were stored at − 70 °C and PAXtubes in − 20 °C until use.
In RA samples, serum IGF1, total cholesterol (TC), triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured by photometry on Cobas 8000. In the samples from 132 ischemic stroke patients, serum IGF1 was measured with a radio-immune assay. Total mRNA was prepared, complementary DNA was synthesized, and amplification of the gene product was attained on a ViiA7 Real-Time PCR.
The scientists reported a low IGF1 resulted in a higher estimated cardiovascular disease (eCVR) in RA patients (7.2% and 3.3%) and in stroke (9.3% and 7.1%). RA had higher rate for new CVD events at prospective follow-up. Hypertension was the major risk factor associated with low IGF1 in RA and stroke. In hypertension, IGF1 was no longer responsible for intracellular activation and lost its correlation to Insulin receptor substrate 1 (IRS1/2) adaptor proteins. The clustering analysis confirmed that combination of low IGF1 and IRS1/2 with high interleukin-6 (IL6), insulin, and glucose predisposed to high eCVR and emphasized the functional role of serum IGF1.
The authors concluded that low serum IGF1 precedes and predicts development of early CVD events in female RA patients. Hypertension and aberrant IGF1 receptor signaling are highlighted as the important contributors to IGF1-related CVD events. The study was published on July 22, 2019, in the journal BMC Medicine.
Related Links:
Sahlgrenska University Hospital
Solid biological evidence connects insulin-like growth factor 1 (IGF1) with the regulation of endothelial cell function. Circulating IGF1 is known to induce vasodilation, which contributes to the regulation of arterial blood pressure (BP) and vascular tone. Disturbances in IGF1/ IGF1 receptor (IGF1R) signaling are notable for RA pathology.
Scientists at Sahlgrenska University Hospital (Gothenburg, Sweden) and their colleagues consecutively enrolled 184 female RA patients. All the patients fulfilled the classification criteria for RA and had median disease duration of seven years. The dominating majority (89%) were Rheumatoid factor (RF) and/or Anti–citrullinated protein antibody (ACPA) positive. For serum preparation, the blood was obtained from the cubital vein into vacuum containers and for RNA preparation into PAXgene protection tubes. Serum samples were stored at − 70 °C and PAXtubes in − 20 °C until use.
In RA samples, serum IGF1, total cholesterol (TC), triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured by photometry on Cobas 8000. In the samples from 132 ischemic stroke patients, serum IGF1 was measured with a radio-immune assay. Total mRNA was prepared, complementary DNA was synthesized, and amplification of the gene product was attained on a ViiA7 Real-Time PCR.
The scientists reported a low IGF1 resulted in a higher estimated cardiovascular disease (eCVR) in RA patients (7.2% and 3.3%) and in stroke (9.3% and 7.1%). RA had higher rate for new CVD events at prospective follow-up. Hypertension was the major risk factor associated with low IGF1 in RA and stroke. In hypertension, IGF1 was no longer responsible for intracellular activation and lost its correlation to Insulin receptor substrate 1 (IRS1/2) adaptor proteins. The clustering analysis confirmed that combination of low IGF1 and IRS1/2 with high interleukin-6 (IL6), insulin, and glucose predisposed to high eCVR and emphasized the functional role of serum IGF1.
The authors concluded that low serum IGF1 precedes and predicts development of early CVD events in female RA patients. Hypertension and aberrant IGF1 receptor signaling are highlighted as the important contributors to IGF1-related CVD events. The study was published on July 22, 2019, in the journal BMC Medicine.
Related Links:
Sahlgrenska University Hospital
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer